Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of glofitamab + GemOx versus rituximab + GemOx in relapsed/refractory diffuse large B-cell lymphoma
CTR20202331Phase 3Active
- Sponsor
- Roche
- Start
- May 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started May 2021; status: active.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20202331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202331.